近日,复星医药(600196.SH;02196.HK)接连获得摩根士丹利(Morgan Stanley)与中信里昂证券(CLSA)两家国际知名投行的积极评价,双双上调其目标股价,并肯定其创新药业务的成长潜力与估值修复空间。市场分析认为,复星医药正迎来价值重估的关键节点。中信里昂证券大幅上调目标价,看好创新药驱动增长中信里昂证券最新的研究报告显示,复星医药2025年第二季度业绩表现稳健,收入环比增长...
Source Link近日,复星医药(600196.SH;02196.HK)接连获得摩根士丹利(Morgan Stanley)与中信里昂证券(CLSA)两家国际知名投行的积极评价,双双上调其目标股价,并肯定其创新药业务的成长潜力与估值修复空间。市场分析认为,复星医药正迎来价值重估的关键节点。中信里昂证券大幅上调目标价,看好创新药驱动增长中信里昂证券最新的研究报告显示,复星医药2025年第二季度业绩表现稳健,收入环比增长...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.